(Reuters) – AstraZeneca on Thursday predicted 2021 revenue growth after COVID-19 vaccine developer hit analysts’ estimates for product sales in the fourth quarter, as range helped wide range of therapies the case from the pandemic.
The British drug dealer said he expects 2021 income to rise with a low teenage percentage, with “faster growth” in basic earnings to $ 4.75 to $ 5.00 per share. Quarterly product sales of $ 7.01 billion exceeded a consensus put together by a company of $ 6.81 billion.
2020 was an important year for AstraZeneca. He teamed up with Oxford University to develop the COVID-19 vaccine, and made the biggest ever deal by buying U.S. drug dealer Alexion for $ 39 billion while betting on drugs with rare disease and immunology.
The London-registered company said its forecast did not include any effects from their COVID-19 vaccine, adding that they planned to break sales out of the picture. starting in the first quarter of this year.
Reporting with Pushkala Aripaka in Bengaluru and Ludwig Burger in Frankfurt. Edited by Shounak Dasgupta and Mark Potter